Tiina Vesterinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiina Vesterinen has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Johanna Arola
Faculty of Medicine University of Helsinki Helsinki Finland
8 shared publications Johanna Arola
Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7 shared publications- Harri Mustonen
Abdominal Center, Department of Gastrointestinal Surgery, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
5 shared publications - Olli Kallioniemi
Institute for Molecular Medicine Finland-FIMM, Helsinki Institute for Life Sciences-HiLIFE, University of Helsinki, Finland
5 shared publications Aija Knuuttila
Department of Pulmonary Medicine, Heart and Lung Center, and Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 shared publications- Antti Rannikko
Department of Urology Helsinki University Hospital Helsinki Finland
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11) , e72441
Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations
Introduction: Pulmonary carcinoids (PCs) are rare, well‐differentiated, neuroendocrine lung tumors with limited treatment options for advanced disease, underscoring the need for targeted therapies. PCs typically exhibit a low mutational burden. Although MEN1 and chromatin‐modifier mutations are known contributors, potentially actionable alterations remain poorly characterized. To better define therapeutic opportunities, we evaluated oncogenic fusions and variants across 17 cancer‐associated genes in a large retrospective PC cohort. Methods: Formalin‐fixed, paraffin‐embedded primary tumors from Helsinki University Hospital ( n = 119, collected between 1990 and 2020) were subjected to targeted RNA‐based fusion and variant analysis using the Archer FusionPlex Lung v2 assay. Results: The most frequent recurrent genetic rearrangements involved ALK ( n = 5), BRAF ( n = 3), FGFR2 ( n = 3), and NTRK3 ( n = 2), each featuring diverse fusion partners. Variant analysis identified BRAF , EGFR , FGFR1 , and FGFR3 as the most frequently mutated genes, although only 2.2% ( n = 4) of all detected variants were classified as oncogenic. Notably, 66.7% of all oncogenic or likely oncogenic variants occurred in BRAF and EGFR . Oncogenic variants were identified in ALK , BRAF , EGFR , and ERBB2 . Although all FGFR1–3 variants were of uncertain significance, their frequency (34.1% of all detected variants), together with the three FGFR2 fusions, suggested that FGFR alterations may be biologically relevant in PCs. Conclusion: Despite the typically muted genomic landscape of PCs, our study revealed a small yet therapeutically relevant subset of alterations. The findings further characterized the molecular profile of PCs and identified potentially actionable molecular subgroups. While these alterations were not associated with disease‐specific survival or metastatic status, they support consideration of molecular profiling in selected patients with advanced disease.
- 29 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11) , e72441
Open AccessGenomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations
Introduction: Pulmonary carcinoids (PCs) are rare, well‐differentiated, neuroendocrine lung tumors with limited treatment options for advanced disease, underscoring the need for targeted therapies. PCs typically exhibit a low mutational burden. Although MEN1 and chromatin‐modifier mutations are known contributors, potentially actionable alterations remain poorly characterized. To better define therapeutic opportunities, we evaluated oncogenic fusions and variants across 17 cancer‐associated genes in a large retrospective PC cohort. Methods: Formalin‐fixed, paraffin‐embedded primary tumors from Helsinki University Hospital ( n = 119, collected between 1990 and 2020) were subjected to targeted RNA‐based fusion and variant analysis using the Archer FusionPlex Lung v2 assay. Results: The most frequent recurrent genetic rearrangements involved ALK ( n = 5), BRAF ( n = 3), FGFR2 ( n = 3), and NTRK3 ( n = 2), each featuring diverse fusion partners. Variant analysis identified BRAF , EGFR , FGFR1 , and FGFR3 as the most frequently mutated genes, although only 2.2% ( n = 4) of all detected variants were classified as oncogenic. Notably, 66.7% of all oncogenic or likely oncogenic variants occurred in BRAF and EGFR . Oncogenic variants were identified in ALK , BRAF , EGFR , and ERBB2 . Although all FGFR1–3 variants were of uncertain significance, their frequency (34.1% of all detected variants), together with the three FGFR2 fusions, suggested that FGFR alterations may be biologically relevant in PCs. Conclusion: Despite the typically muted genomic landscape of PCs, our study revealed a small yet therapeutically relevant subset of alterations. The findings further characterized the molecular profile of PCs and identified potentially actionable molecular subgroups. While these alterations were not associated with disease‐specific survival or metastatic status, they support consideration of molecular profiling in selected patients with advanced disease.
- Open Access
- 18 September 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (10)
Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines
- 18 September 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (10)
Open AccessAnagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines
- Open Access
- 5 July 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (11) , 1493-1498
Estimating the use of biological samples in Finnish biobanks and hospital collections
Finland has steadily developed its biobanking infrastructures since the early 2010s. This article presents a systematic overview of the number of biological samples that have been provided for research since 2013 when the Finnish Biobank Act came into force. Using data from individual biobanks and from permits issued by Fimea (formerly Valvira), we present the most up-to-date and complete account of sample use at a national level. Between 2014 and 2023 a total of 1,474,881 samples were provided through 998 sample requests. A better understanding of the use of biological samples at the national level can help highlight the important impact biobanking has as an infrastructure for supporting research. We argue that developing standards can help in developing national biobanking strategies and identify areas where biobanking can be further developed. We also conclude that the ability to combine tissue samples and health data flexibly and efficiently is essential and needs to be secured also within the context of the European Health Data Space (EHDS).
- 5 July 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (11) , 1493-1498
Open AccessEstimating the use of biological samples in Finnish biobanks and hospital collections
Finland has steadily developed its biobanking infrastructures since the early 2010s. This article presents a systematic overview of the number of biological samples that have been provided for research since 2013 when the Finnish Biobank Act came into force. Using data from individual biobanks and from permits issued by Fimea (formerly Valvira), we present the most up-to-date and complete account of sample use at a national level. Between 2014 and 2023 a total of 1,474,881 samples were provided through 998 sample requests. A better understanding of the use of biological samples at the national level can help highlight the important impact biobanking has as an infrastructure for supporting research. We argue that developing standards can help in developing national biobanking strategies and identify areas where biobanking can be further developed. We also conclude that the ability to combine tissue samples and health data flexibly and efficiently is essential and needs to be secured also within the context of the European Health Data Space (EHDS).
- Open Access
- 18 June 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 983-991
Phosphodiesterase 3 A expression in gastrointestinal stromal tumors
Phosphodiesterase 3A (PDE3A) is an emerging therapy target in various cancers with high expression, as in the majority of gastrointestinal stromal tumors (GISTs). However, its association with clinicopathological factors and patient survival in GISTs remains unexplored. We investigated PDE3A expression using a novel mouse monoclonal antibody and immunohistochemistry in two GIST patient series consisting of 173 formalin-fixed, paraffin-embedded tissue samples on tissue microarrays. In addition, we analyzed the association between PDE3A staining intensity and clinicopathological variables and patient survival. We also assessed PDE3A mRNA expression using qPCR in a subset of the samples. We found that all GISTs expressed PDE3A. The staining pattern was weak in 6.3%, intermediate in 35.8%, and strong in 57.8% of tumors. Weak PDE3A expression was associated with a lower median mitotic count (1/50 HPF vs. 4/50 HPF vs. 5/50 HPF; p = 0.007) and higher incidence of metastases at diagnosis (28% vs. 8% vs. 3.3%; p = 0.040) than in tumors with intermediate or strong expression, respectively. PDE3A and CD117 staining intensities correlated positively ( p < 0.001), but PDE3A expression showed no association with sex, age, tumor size, location, risk stratification, mutation profile, Schlafen 12 expression, or metastasis-free or overall survival. We conclude that PDE3A expression can be reliably assessed in archived tumor material using immunohistochemistry. GISTs, with their consistently high PDE3A expression, are a promising target for PDE3A-targeted therapies. This method may also aid in stratifying patients in cancers where PDE3A expression is less common.
- 18 June 2025
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (5) , 983-991
Open AccessPhosphodiesterase 3 A expression in gastrointestinal stromal tumors
Phosphodiesterase 3A (PDE3A) is an emerging therapy target in various cancers with high expression, as in the majority of gastrointestinal stromal tumors (GISTs). However, its association with clinicopathological factors and patient survival in GISTs remains unexplored. We investigated PDE3A expression using a novel mouse monoclonal antibody and immunohistochemistry in two GIST patient series consisting of 173 formalin-fixed, paraffin-embedded tissue samples on tissue microarrays. In addition, we analyzed the association between PDE3A staining intensity and clinicopathological variables and patient survival. We also assessed PDE3A mRNA expression using qPCR in a subset of the samples. We found that all GISTs expressed PDE3A. The staining pattern was weak in 6.3%, intermediate in 35.8%, and strong in 57.8% of tumors. Weak PDE3A expression was associated with a lower median mitotic count (1/50 HPF vs. 4/50 HPF vs. 5/50 HPF; p = 0.007) and higher incidence of metastases at diagnosis (28% vs. 8% vs. 3.3%; p = 0.040) than in tumors with intermediate or strong expression, respectively. PDE3A and CD117 staining intensities correlated positively ( p < 0.001), but PDE3A expression showed no association with sex, age, tumor size, location, risk stratification, mutation profile, Schlafen 12 expression, or metastasis-free or overall survival. We conclude that PDE3A expression can be reliably assessed in archived tumor material using immunohistochemistry. GISTs, with their consistently high PDE3A expression, are a promising target for PDE3A-targeted therapies. This method may also aid in stratifying patients in cancers where PDE3A expression is less common.
- Open Access
- 19 June 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 486 (4) , 675-685
Absence of orthopaedia homeobox protein (OTP) expression is associated with disease spread and adverse outcome in pulmonary carcinoid tumour patients
Pulmonary carcinoid (PC) tumours typically have a good prognosis, although metastases occur, and the disease may progress after a long period of time. Expression of orthopaedia homeobox protein (OTP) has been recognized as a possible independent prognostic marker in PCs. Immunohistochemical (IHC) OTP expression has been associated with better prognosis, but the staining has yet to be implemented in routine clinical diagnostics. In response to this, two new monoclonal OTP antibodies were recently developed. This retrospective study included 164 PC patients operated on at Helsinki University Hospital between 1990 and 2020. Tissue microarray slides, prepared from formalin-fixed and paraffin-embedded primary tumour samples, were stained with OTP IHC using one polyclonal and two novel monoclonal antibodies. Absence of OTP expression was associated with a shorter disease-specific survival (DSS) and disease progression (p < 0.001). Patients without OTP expression had a 5-year DSS of 73–79%, whereas 5-year DSS was 91–94% with OTP expression, depending on the primary antibody. In a univariable Cox regression model, absence of OTP expression was associated with adverse outcome along with atypical histological subtype, metastatic disease, Ki-67 proliferation index > 1%, and larger tumour size. In a multivariable Cox regression model, only absence of OTP expression and lymph node involvement at the time of diagnosis were associated with risk of worse prognosis. All three antibodies showed good concordance with each other. Our findings support the role of OTP as an independent prognostic marker in PCs and applicability of IHC staining in routine clinical use with novel monoclonal antibodies.
- 19 June 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 486 (4) , 675-685
Open AccessAbsence of orthopaedia homeobox protein (OTP) expression is associated with disease spread and adverse outcome in pulmonary carcinoid tumour patients
Pulmonary carcinoid (PC) tumours typically have a good prognosis, although metastases occur, and the disease may progress after a long period of time. Expression of orthopaedia homeobox protein (OTP) has been recognized as a possible independent prognostic marker in PCs. Immunohistochemical (IHC) OTP expression has been associated with better prognosis, but the staining has yet to be implemented in routine clinical diagnostics. In response to this, two new monoclonal OTP antibodies were recently developed. This retrospective study included 164 PC patients operated on at Helsinki University Hospital between 1990 and 2020. Tissue microarray slides, prepared from formalin-fixed and paraffin-embedded primary tumour samples, were stained with OTP IHC using one polyclonal and two novel monoclonal antibodies. Absence of OTP expression was associated with a shorter disease-specific survival (DSS) and disease progression (p < 0.001). Patients without OTP expression had a 5-year DSS of 73–79%, whereas 5-year DSS was 91–94% with OTP expression, depending on the primary antibody. In a univariable Cox regression model, absence of OTP expression was associated with adverse outcome along with atypical histological subtype, metastatic disease, Ki-67 proliferation index > 1%, and larger tumour size. In a multivariable Cox regression model, only absence of OTP expression and lymph node involvement at the time of diagnosis were associated with risk of worse prognosis. All three antibodies showed good concordance with each other. Our findings support the role of OTP as an independent prognostic marker in PCs and applicability of IHC staining in routine clinical use with novel monoclonal antibodies.
- Open Access
- 13 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15164
Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
Insulinomas are rare functional pancreatic neuroendocrine tumours, which metastasize in 10% of cases. As predicting the prognosis can be challenging, there is a need for the determination of clinicopathological factors associated with metastatic potential. The aim of this study is to evaluate the glucagon-like peptide-1 receptor (GLP-1R) expression in insulinomas and to analyse its association with clinicopathological features and patient outcome. This retrospective study involves pancreatic tumour tissue samples from fifty-two insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with a monoclonal GLP-1R antibody. Forty-eight of the forty-nine (98%) non-metastatic tumours expressed GLP-1R, while one non-metastatic, multiple endocrine neoplasia type 1 (MEN1)-related tumour and all three of the metastatic tumours lacked GLP-1R expression. The lack of GLP-1R expression was associated with impaired overall survival, larger tumour diameter, higher Ki-67 PI and weaker insulin staining. Somatostatin receptor 1–5 expression did not differ between GLP-1R-positive and GLP-1R-negative insulinomas. In conclusion, the lack of GLP-1R expression is associated with metastatic disease and impaired survival in insulinoma patients. Thus, GLP-1R expression could be a useful biomarker in estimating the metastatic potential of the tumour and the prognosis of surgically treated patients.
- 13 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15164
Open AccessImmunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
Insulinomas are rare functional pancreatic neuroendocrine tumours, which metastasize in 10% of cases. As predicting the prognosis can be challenging, there is a need for the determination of clinicopathological factors associated with metastatic potential. The aim of this study is to evaluate the glucagon-like peptide-1 receptor (GLP-1R) expression in insulinomas and to analyse its association with clinicopathological features and patient outcome. This retrospective study involves pancreatic tumour tissue samples from fifty-two insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with a monoclonal GLP-1R antibody. Forty-eight of the forty-nine (98%) non-metastatic tumours expressed GLP-1R, while one non-metastatic, multiple endocrine neoplasia type 1 (MEN1)-related tumour and all three of the metastatic tumours lacked GLP-1R expression. The lack of GLP-1R expression was associated with impaired overall survival, larger tumour diameter, higher Ki-67 PI and weaker insulin staining. Somatostatin receptor 1–5 expression did not differ between GLP-1R-positive and GLP-1R-negative insulinomas. In conclusion, the lack of GLP-1R expression is associated with metastatic disease and impaired survival in insulinoma patients. Thus, GLP-1R expression could be a useful biomarker in estimating the metastatic potential of the tumour and the prognosis of surgically treated patients.
- Open Access
- 4 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (9) , 1001-1007
Somatostatin receptor expression in Merkel cell carcinoma: correlation with clinical data
Merkel cell carcinoma (MCC) is a rare, high-grade neuroendocrine neoplasm (NEN) of the skin. Somatostatin receptors (SSTRs) are G protein-linked receptors that regulate cell proliferation and growth. SSTRs are expressed in many NENs; however, scant information is available on their expression in MCCs or their association with clinical parameters and patient outcomes. This retrospective study was conducted at Helsinki University Hospital and the University of Helsinki. Using a tissue microarray, we investigated SSTR1-5 expression by immunohistochemistry in 99 MCC tissue samples. Samples were collected between 1983 and 2017 and coupled with the patients' clinical data. SSTR2-SSTR5 were detected in 69%, 6%, 4%, and 1% of the tumours, respectively. However, SSTR1 expression was not observed. Cytoplasmic SSTR2 positivity was associated with metastatic disease at the time of diagnosis (p = 0.009), but it did not correlate with disease-specificity or overall survival. SSTR2-5 expression was observed in MCCs. In particular, SSTR2 expression is clinically valid because it is associated with metastatic disease at the time of diagnosis and can thus serve as a prognostic marker. Moreover, SSTR2 overexpression provides a molecular basis for tumour imaging and treatment with somatostatin analogues.
- 4 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (9) , 1001-1007
Open AccessSomatostatin receptor expression in Merkel cell carcinoma: correlation with clinical data
Merkel cell carcinoma (MCC) is a rare, high-grade neuroendocrine neoplasm (NEN) of the skin. Somatostatin receptors (SSTRs) are G protein-linked receptors that regulate cell proliferation and growth. SSTRs are expressed in many NENs; however, scant information is available on their expression in MCCs or their association with clinical parameters and patient outcomes. This retrospective study was conducted at Helsinki University Hospital and the University of Helsinki. Using a tissue microarray, we investigated SSTR1-5 expression by immunohistochemistry in 99 MCC tissue samples. Samples were collected between 1983 and 2017 and coupled with the patients' clinical data. SSTR2-SSTR5 were detected in 69%, 6%, 4%, and 1% of the tumours, respectively. However, SSTR1 expression was not observed. Cytoplasmic SSTR2 positivity was associated with metastatic disease at the time of diagnosis (p = 0.009), but it did not correlate with disease-specificity or overall survival. SSTR2-5 expression was observed in MCCs. In particular, SSTR2 expression is clinically valid because it is associated with metastatic disease at the time of diagnosis and can thus serve as a prognostic marker. Moreover, SSTR2 overexpression provides a molecular basis for tumour imaging and treatment with somatostatin analogues.
- Open Access
Immunohistochemical somatostatin receptor expression in insulinomas
Insulinomas are rare pancreatic neuroendocrine tumours. Most patients can be cured with surgery, but patients with a metastatic disease show impaired survival. The aim of this study was to evaluate somatostatin receptor (SSTR) 1-5 expression in insulinomas and to correlate the expression profile with clinicopathological variables and with patient outcome. This retrospective study involved 52 insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with monoclonal SSTR1-5 antibodies. All the 52 tumours (49 non-metastatic, 3 metastatic) expressed at least one SSTR subtype. SSTR2 was expressed most frequently (71%), followed by SSTR3 (33%), SSTR1 (27%), SSTR5 (6%) and SSTR4 (0%). SSTR3 expression was associated with a larger tumour size (median diameter 19 mm vs. 13 mm, p = 0.043), and SSTR3 and SSTR5 expression were associated with impaired overall survival [HR 3.532 (95% CI 1.106-11,277), p = 0.033, and HR 6.805 (95% CI 1.364-33.955), p = 0.019 respectively]. Most insulinomas express SSTR2, which may be utilized in diagnostic imaging, and in planning individualized treatment strategies for insulinoma patients. Further studies are needed to clarify the association between SSTR profile and overall survival.
Open AccessImmunohistochemical somatostatin receptor expression in insulinomas
Insulinomas are rare pancreatic neuroendocrine tumours. Most patients can be cured with surgery, but patients with a metastatic disease show impaired survival. The aim of this study was to evaluate somatostatin receptor (SSTR) 1-5 expression in insulinomas and to correlate the expression profile with clinicopathological variables and with patient outcome. This retrospective study involved 52 insulinoma patients. After histological re-evaluation, formalin-fixed paraffin-embedded tissue samples were processed into tissue microarrays and stained immunohistochemically with monoclonal SSTR1-5 antibodies. All the 52 tumours (49 non-metastatic, 3 metastatic) expressed at least one SSTR subtype. SSTR2 was expressed most frequently (71%), followed by SSTR3 (33%), SSTR1 (27%), SSTR5 (6%) and SSTR4 (0%). SSTR3 expression was associated with a larger tumour size (median diameter 19 mm vs. 13 mm, p = 0.043), and SSTR3 and SSTR5 expression were associated with impaired overall survival [HR 3.532 (95% CI 1.106-11,277), p = 0.033, and HR 6.805 (95% CI 1.364-33.955), p = 0.019 respectively]. Most insulinomas express SSTR2, which may be utilized in diagnostic imaging, and in planning individualized treatment strategies for insulinoma patients. Further studies are needed to clarify the association between SSTR profile and overall survival.
- Open Access
Tensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors
GIST is a rare soft tissue sarcoma, for which KIT and DOG1 are used as highly sensitive diagnostic markers. Other diagnostic markers include CD34, protein kinase C θ, deficiency of succinate dehydrogenase complex subunit B, carbonic anhydrase II, and type I insulin-like growth factor receptor. We investigated the role of TNS2 as a diagnostic biomarker by using immunohistochemistry in 176 GISTs and 521 other sarcomas. All GISTs expressed TNS2, with intermediate or high expression in 71.4% of samples. The majority (89.8%) of other sarcomas were negative for TNS2, and intermediate to strong staining was only seen in 2.9% of samples. Strong TNS2 staining was associated with gastric location (gastric 52.8% vs. non-gastric 7.2%; p < 0.001), absence of metastases (non-metastatic tumors 44.3% vs. metastatic tumors 5.9%; p = 0.004), female sex (female 45.9% vs. male 33.8%; p = 0.029), and tumors of lower risk categories (very low or low 46.9% vs. intermediate 51.7% vs. high 29.0%; p = 0.020). TNS2 expression did not correlate with overall survival or metastasis-free survival. No associations between TNS2 expression and KIT/PDGFRA mutation status, tumor size, mitotic count, or age of the patient were detected. The results provide conclusive evidence for the value of TNS2 as a sensitive and specific diagnostic biomarker for GIST.
Open AccessTensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors
GIST is a rare soft tissue sarcoma, for which KIT and DOG1 are used as highly sensitive diagnostic markers. Other diagnostic markers include CD34, protein kinase C θ, deficiency of succinate dehydrogenase complex subunit B, carbonic anhydrase II, and type I insulin-like growth factor receptor. We investigated the role of TNS2 as a diagnostic biomarker by using immunohistochemistry in 176 GISTs and 521 other sarcomas. All GISTs expressed TNS2, with intermediate or high expression in 71.4% of samples. The majority (89.8%) of other sarcomas were negative for TNS2, and intermediate to strong staining was only seen in 2.9% of samples. Strong TNS2 staining was associated with gastric location (gastric 52.8% vs. non-gastric 7.2%; p < 0.001), absence of metastases (non-metastatic tumors 44.3% vs. metastatic tumors 5.9%; p = 0.004), female sex (female 45.9% vs. male 33.8%; p = 0.029), and tumors of lower risk categories (very low or low 46.9% vs. intermediate 51.7% vs. high 29.0%; p = 0.020). TNS2 expression did not correlate with overall survival or metastasis-free survival. No associations between TNS2 expression and KIT/PDGFRA mutation status, tumor size, mitotic count, or age of the patient were detected. The results provide conclusive evidence for the value of TNS2 as a sensitive and specific diagnostic biomarker for GIST.